Literature DB >> 26170912

Inhibition of intimal hyperplasia via local delivery of vascular endothelial growth factor cDNA nanoparticles in a rabbit model of restenosis induced by abdominal aorta balloon injury.

Hongzhi Xie1, Jing Yang2, Yechen Han1, Xueqing Zhu1, Quan Fang1.   

Abstract

In-stent restenosis (ISR) is one of the major factors affecting long-term outcomes of percutaneous coronary interventions. Vascular endothelial growth factor (VEGF) has been hypothesized to have a positive role in preventing ISR, however, this remains controversial. The aim of the present study was to assess whether nanoparticles can be used to deliver VEGF to injured arteries and whether this is beneficial in preventing restenosis. New Zealand White rabbits were randomly divided into a control group, an empty nanoparticles group and a VEGF nanoparticles group (n=6 in each group). Polylactic-polyglycolic acid VEGF nanoparticles were prepared using a phacoemulsification method. A rabbit model of restenosis was established following abdominal aorta balloon injury, and VEGF gene nanoparticles, empty nanoparticles or normal saline were delivered locally at the site of injury via a GENIE Catheter™ perfusion balloon. Intimal proliferation determination and immunohistochemistry analysis were performed at day 28 following arterial injury. Compared with the control and empty nanoparticle groups, the neointima area (0.49±0.09, 0.48±0.08 and 0.19±0.11 mm2, respectively; P<0.001) and proliferation index (0.32±0.03, 0.32±0.05 and 0.13±0.06, respectively; P<0.001) were significantly lower in the VEGF nanoparticles group. In addition, in the VEGF nanoparticles group, the immunoreactivity of α-actin and proliferating cell nuclear antigen were significantly lower (P≤0.001), while the immunoreactivity of VEGF was higher (P=0.01). Therefore, the results revealed that local delivery of VEGF gene nanoparticles reduced intimal thickening and cell proliferation following abdominal aorta balloon injury in a rabbit model, demonstrating the efficacy of this therapy against restenosis.

Entities:  

Keywords:  balloon injury; gene therapy; nanoparticles; restenosis; vascular endothelial growth factor

Year:  2015        PMID: 26170912      PMCID: PMC4486805          DOI: 10.3892/etm.2015.2438

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  39 in total

1.  Guiding principles for research involving animals and human beings.

Authors: 
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-12       Impact factor: 4.733

2.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.

Authors:  Y Zhang; N Chirmule; G P Gao; R Qian; M Croyle; B Joshi; J Tazelaar; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

3.  Experimental study of adenovirus vector mediated-hVEGF165 gene on prevention of restenosis after angioplasty.

Authors:  Qigong Liu; Zaiying Lu; Yuankun Yue; Li Lin; Weidong Zhang; Jin Yan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

4.  Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth.

Authors:  Justin S Golub; Young-tae Kim; Craig L Duvall; Ravi V Bellamkonda; Divya Gupta; Angela S Lin; Daiana Weiss; W Robert Taylor; Robert E Guldberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-12       Impact factor: 4.733

5.  Effects of local gene transfer of VEGF on neointima formation after balloon injury in hypercholesterolemic rabbits.

Authors:  Jozef Dulak; Severin P Schwarzacher; Ralf H Zwick; Hannes Alber; Gunda Millonig; Caecilia Weiss; Heike Hügel; Matthias Frick; Alicja Jozkowicz; Otmar Pachinger; Franz Weidinger
Journal:  Vasc Med       Date:  2005-11       Impact factor: 3.239

6.  Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.

Authors:  T Nagae; K Aizawa; N Uchimura; D Tani; M Abe; K Fujishima; S E Wilson; S Ishimaru
Journal:  Lasers Surg Med       Date:  2001       Impact factor: 4.025

7.  Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism.

Authors:  J Rutanen; A-M Turunen; M Teittinen; T T Rissanen; T Heikura; J K Koponen; M Gruchala; M Inkala; S Jauhiainen; M O Hiltunen; M P Turunen; S A Stacker; M G Achen; S Ylä-Herttuala
Journal:  Gene Ther       Date:  2005-06       Impact factor: 5.250

8.  Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy.

Authors:  Thomas Wirth; Marja Hedman; Kimmo Mäkinen; Hannu Manninen; Arto Immonen; Matti Vapalahti; Seppo Ylä-Herttuala
Journal:  Curr Drug Saf       Date:  2006-08

9.  Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer.

Authors:  M Hedman; K Muona; A Hedman; A Kivelä; M Syvänne; J Eränen; A Rantala; J Stjernvall; M S Nieminen; J Hartikainen; S Ylä-Herttuala
Journal:  Gene Ther       Date:  2009-02-12       Impact factor: 5.250

10.  Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; K Dee Carey; Milton Finegold; Philip Ng
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

View more
  2 in total

Review 1.  Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.

Authors:  Hui Xu; Shuang Li; You-Shuo Liu
Journal:  Signal Transduct Target Ther       Date:  2022-07-11

2.  An Ex Vivo Vessel Injury Model to Study Remodeling.

Authors:  Mehmet H Kural; Guohao Dai; Laura E Niklason; Liqiong Gui
Journal:  Cell Transplant       Date:  2018-08-10       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.